Abstract
Respiratory syncytial virus (RSV) is a very important pathogen worldwide. It occurs and recurs naturally throughout life. Both short and long term morbidity, and mortality are particularly significant for infants, especially those infants with underlying conditions and risk factors. Current treatment strategies for these patients (e.g Ribavirin) are limited but several new interventions (e.g. RSV604, BTA9881, ALN-RSV01) are under investigation. Several preventive agents and strategies have been developed (e.g. RSV-IGIV, palivizumab) and others are in the pipeline (e.g. motavizumab) and under development (e,g, Medi-557). In this article, we review the RSV clinical condition with a focus on the highest risk populations. In addition we review prevention and treatment strategies of the past, present and future for these high-risk patients. This review should provide a single valuable source of information to clinicians and investigators.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Respiratory Syncytial Virus (RSV) Prevention and Treatment: Past, Present, and Future
Volume: 7 Issue: 3
Author(s): Leonard E. Weisman
Affiliation:
Abstract: Respiratory syncytial virus (RSV) is a very important pathogen worldwide. It occurs and recurs naturally throughout life. Both short and long term morbidity, and mortality are particularly significant for infants, especially those infants with underlying conditions and risk factors. Current treatment strategies for these patients (e.g Ribavirin) are limited but several new interventions (e.g. RSV604, BTA9881, ALN-RSV01) are under investigation. Several preventive agents and strategies have been developed (e.g. RSV-IGIV, palivizumab) and others are in the pipeline (e.g. motavizumab) and under development (e,g, Medi-557). In this article, we review the RSV clinical condition with a focus on the highest risk populations. In addition we review prevention and treatment strategies of the past, present and future for these high-risk patients. This review should provide a single valuable source of information to clinicians and investigators.
Export Options
About this article
Cite this article as:
Weisman E. Leonard, Respiratory Syncytial Virus (RSV) Prevention and Treatment: Past, Present, and Future, Cardiovascular & Hematological Agents in Medicinal Chemistry 2009; 7 (3) . https://dx.doi.org/10.2174/187152509789105471
DOI https://dx.doi.org/10.2174/187152509789105471 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Transesophageal Echocardiography in the Intraoperative Period
Current Cardiology Reviews Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy Endothelial Dysfunction in Morbid Obesity
Current Pharmaceutical Design Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Biomarkers Associated with Atrial Fibrosis and Remodeling
Current Medicinal Chemistry Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry OPA1 in Cardiovascular Health and Disease
Current Drug Targets Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?
Current Cardiology Reviews Twenty Years of Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy
Current Cardiology Reviews Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention
Current Drug Targets Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery Anti-T. cruzi Agents: Our Experience in the Evaluation of More than Five Hundred Compounds
Mini-Reviews in Medicinal Chemistry Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets
Current Drug Targets Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling
Current Stem Cell Research & Therapy Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review
Current Cardiology Reviews Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Altered Calcium Handling in Reperfusion Injury
Medicinal Chemistry